CN101484169A - 包含纳米颗粒美洛昔康和控释氢可酮的组合物 - Google Patents

包含纳米颗粒美洛昔康和控释氢可酮的组合物 Download PDF

Info

Publication number
CN101484169A
CN101484169A CNA2007800235166A CN200780023516A CN101484169A CN 101484169 A CN101484169 A CN 101484169A CN A2007800235166 A CNA2007800235166 A CN A2007800235166A CN 200780023516 A CN200780023516 A CN 200780023516A CN 101484169 A CN101484169 A CN 101484169A
Authority
CN
China
Prior art keywords
hydrocodone
composition
compositions
release
meloxicam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800235166A
Other languages
English (en)
Chinese (zh)
Inventor
P·斯塔克
J·德韦恩
N·范宁
G·里弗斯德格
S·简金斯
G·辛格-雷克伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of CN101484169A publication Critical patent/CN101484169A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800235166A 2006-06-23 2007-06-25 包含纳米颗粒美洛昔康和控释氢可酮的组合物 Pending CN101484169A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81588406P 2006-06-23 2006-06-23
US60/815,884 2006-06-23

Publications (1)

Publication Number Publication Date
CN101484169A true CN101484169A (zh) 2009-07-15

Family

ID=38834447

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800235166A Pending CN101484169A (zh) 2006-06-23 2007-06-25 包含纳米颗粒美洛昔康和控释氢可酮的组合物

Country Status (11)

Country Link
EP (1) EP2032139A4 (no)
JP (1) JP2009541360A (no)
KR (1) KR20090023729A (no)
CN (1) CN101484169A (no)
AU (1) AU2007260822B2 (no)
CA (1) CA2660650A1 (no)
IL (1) IL196066A0 (no)
MX (1) MX2008016115A (no)
NO (1) NO20090119L (no)
WO (1) WO2007150075A2 (no)
ZA (1) ZA200810098B (no)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104203169A (zh) * 2011-12-29 2014-12-10 安德罗玛克实验室股份有限公司 包含美洛昔康和调节所述活性成分的释放的试剂的阴道环，其可用作在女性中连续使用的避孕药
CN113181249A (zh) * 2021-05-25 2021-07-30 重庆市畜牧科学院 一种抗仔猪腹泻的中药缓释颗粒的制备方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
BRPI1014275B8 (pt) 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
CA2763456C (en) * 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
SG10201510564PA (en) 2010-12-22 2016-01-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
CN103070906A (zh) * 2011-12-08 2013-05-01 赵联华 一种治疗骨科疾病的注射用组合物的质量控制方法
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2021257784A1 (en) * 2020-06-18 2021-12-23 Verté Therapeutics, Llc Injectable meloxicam formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
KR20070051953A (ko) * 1998-11-02 2007-05-18 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
HU230828B1 (en) * 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1443912B1 (en) * 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions having a combination of immediate release and controlled release characteristics
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104203169A (zh) * 2011-12-29 2014-12-10 安德罗玛克实验室股份有限公司 包含美洛昔康和调节所述活性成分的释放的试剂的阴道环，其可用作在女性中连续使用的避孕药
CN104203169B (zh) * 2011-12-29 2016-07-13 安德罗玛克实验室股份有限公司 包含美洛昔康和调节所述活性成分的释放的试剂的阴道环，其可用作在女性中连续使用的避孕药
CN113181249A (zh) * 2021-05-25 2021-07-30 重庆市畜牧科学院 一种抗仔猪腹泻的中药缓释颗粒的制备方法
CN113181249B (zh) * 2021-05-25 2022-06-14 重庆市畜牧科学院 一种抗仔猪腹泻的中药缓释颗粒的制备方法

Also Published As

Publication number Publication date
WO2007150075A3 (en) 2008-04-24
KR20090023729A (ko) 2009-03-05
EP2032139A4 (en) 2012-08-22
EP2032139A2 (en) 2009-03-11
CA2660650A1 (en) 2007-12-27
MX2008016115A (es) 2009-01-20
NO20090119L (no) 2009-03-20
ZA200810098B (en) 2009-12-30
JP2009541360A (ja) 2009-11-26
WO2007150075A2 (en) 2007-12-27
IL196066A0 (en) 2009-09-01
AU2007260822B2 (en) 2012-07-05
AU2007260822A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
CN101484169A (zh) 包含纳米颗粒美洛昔康和控释氢可酮的组合物
CN101484170A (zh) 包含纳米颗粒萘普生和控释氢可酮的组合物
US20080102121A1 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
CN101171000A (zh) 包含环孢菌素的毫微粒和控制释放组合物
TWI558422B (zh) 減少奈米顆粒活性劑組成物中薄片狀聚集之技術
CN101495096A (zh) 纳米微粒泊沙康唑制剂
EP2790699B2 (en) Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound
CN101237868A (zh) 纳米粒氯吡格雷和阿司匹林组合制剂
CN101259106A (zh) 含有头孢菌素的纳米控释组合物
US20080113025A1 (en) Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
MX2011010620A (es) Composicion de suministro de farmaco.
TR201809084T4 (tr) Lopinavir içeren katı farmasötik dozaj formülasyonu.
CN101262860A (zh) 纳米微粒对乙酰氨基酚制剂
CN101232870A (zh) 纳米微粒甲磺酸伊马替尼制剂
JP2007501839A (ja) 新規メタキサロン組成物
EA013741B1 (ru) Дисперсии наночастиц такролимуса с повышенными растворимостью в воде и биодоступностью, способы их приготовления и применения
CN101287453A (zh) 包含头孢菌素的毫微粒和控制释放组合物
CN101426477A (zh) 纳米颗粒卡维地洛制剂
CN101287451A (zh) 包含血小板聚集抑制剂的毫微粒和控制释放组合物
US20150342893A1 (en) Celecoxib formulations useful for treating colorectal cancer
JP2009543803A (ja) モダフィニルのナノ粒子製剤
CN101879140A (zh) 包含芳基-杂环化合物的毫微粒和控制释放组合物
CN101132768A (zh) 纳米颗粒他克莫司制剂
JP2007522079A (ja) ニメスリド組成物
JP2009517485A (ja) セフジトレンを含むナノ粒子状および制御放出組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication